SELLAS Nearing Phase 3 Milestone as Cash Reserves and Early Data Bolster Outlook
Approaching REGAL Phase 3 Data Will Define Next Steps
SELLAS Life Sciences (NASDAQ:SLS) is fast approaching a major inflection point as its pivotal Phase 3 REGAL trial in acute myeloid leukemia (AML) nears the pre-specified 80-event trigger for final analysis. With 78 events reported as of May 11, 2026, the company remains blinded to outcomes but anticipates the important data readout soon. This milestone could shape prospects for its lead candidate, galinpepimut-S (GPS), especially as top-line results will follow database lock and data review procedures after the final event.
SLS009 Shows Promise in Hard-to-Treat AML Subtypes
Alongside GPS, SELLAS advanced the Phase 2 trial of SLS009 (tambiciclib), a novel CDK9 inhibitor, in newly diagnosed first-line AML patients, including those with high-risk genetic profiles. Preclinical findings showcased at AACR 2026 suggest SLS009 drives apoptosis—even in cell lines with typically poor prognostic markers like TP53 and ASXL1 mutations. These data strengthen the case for SLS009 as a differentiated asset among emerging AML therapeutics, with topline clinical results expected in Q4 2026.
Cash Position Provides Strategic Flexibility
The company’s balance sheet is notable. As of March 31, 2026, SELLAS reported $107.1 million in cash and equivalents, with another $7.5 million added in Q2 from warrant exercises. This bolsters financial flexibility as SELLAS prepares for potential commercialization and ongoing trial expenses. Importantly, the company’s at-the-market (ATM) equity facility remains untapped, further strengthening near-term runway.
| Q1 2026 | Q1 2025 |
|---|---|
| Cash & Equivalents: $107.10 million | $71.79 million |
| R&D Expenses: $5.13 million | $3.21 million |
| G&A Expenses: $4.12 million | $2.86 million |
| Net Loss: $8.41 million | $5.81 million |
| Net Loss per Share: $0.05 | $0.07 |
| Shares Outstanding: 172,481,541 | 87,760,320 |
Operational Investments Lay Groundwork for Scalability
R&D and G&A spending increased year-over-year, reflecting investment in manufacturing, clinical trials, and readiness for a potential Biologics License Application for GPS. With a higher share count and a reduced net loss per share, capital raises and warrant exercises have reinforced SELLAS’ position for the next phase of growth.
Multiple Catalysts on the Horizon
2026 is shaping up as a transformative year for SELLAS. The imminent data from the REGAL study, advancing SLS009, and a robust cash runway mean investors will have a series of pivotal milestones to track. With clinical, financial, and corporate updates converging, the upcoming months could redefine SELLAS’s place in the AML landscape. As always, the real test will be whether the looming REGAL readout can deliver results as compelling as the company’s strategic positioning suggests.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI